HC Wainwright Reaffirms Buy Rating for Aquestive Therapeutics (NASDAQ:AQST)

HC Wainwright reiterated their buy rating on shares of Aquestive Therapeutics (NASDAQ:AQST - Free Report) in a report released on Wednesday morning,Benzinga reports. They currently have a $10.00 price objective on the stock.

AQST has been the topic of a number of other reports. Cantor Fitzgerald began coverage on shares of Aquestive Therapeutics in a research note on Tuesday, December 17th. They issued an "overweight" rating and a $17.00 target price on the stock. Raymond James set a $7.00 target price on shares of Aquestive Therapeutics in a research note on Friday, March 7th. Lake Street Capital reduced their price target on shares of Aquestive Therapeutics from $10.00 to $8.00 and set a "buy" rating on the stock in a research note on Friday, March 7th. Finally, Alliance Global Partners reiterated a "buy" rating on shares of Aquestive Therapeutics in a report on Friday, March 7th. Seven research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company's stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Buy" and a consensus price target of $10.57.

Aquestive Therapeutics Stock Down 5.7 %

Shares of NASDAQ AQST traded down $0.16 during midday trading on Wednesday, reaching $2.56. 805,302 shares of the stock were exchanged, compared to its average volume of 1,583,147. The firm has a 50-day simple moving average of $2.97 and a two-hundred day simple moving average of $3.87. Aquestive Therapeutics has a twelve month low of $2.24 and a twelve month high of $5.80. The firm has a market cap of $252.62 million, a price-to-earnings ratio of -5.70 and a beta of 2.59.

Aquestive Therapeutics (NASDAQ:AQST - Get Free Report) last announced its earnings results on Wednesday, March 5th. The company reported ($0.19) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.14) by ($0.05). The firm had revenue of $11.87 million during the quarter, compared to analysts' expectations of $13.11 million. Research analysts expect that Aquestive Therapeutics will post -0.46 EPS for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the company. New York State Common Retirement Fund raised its holdings in shares of Aquestive Therapeutics by 713.3% in the 4th quarter. New York State Common Retirement Fund now owns 12,200 shares of the company's stock valued at $43,000 after purchasing an additional 10,700 shares in the last quarter. Dynamic Technology Lab Private Ltd purchased a new stake in Aquestive Therapeutics during the 4th quarter worth about $44,000. Two Sigma Advisers LP acquired a new position in shares of Aquestive Therapeutics during the 4th quarter worth about $57,000. PKS Advisory Services LLC purchased a new position in Aquestive Therapeutics in the fourth quarter valued at approximately $63,000. Finally, Intech Investment Management LLC purchased a new position in shares of Aquestive Therapeutics in the 3rd quarter valued at $90,000. Hedge funds and other institutional investors own 32.45% of the company's stock.

About Aquestive Therapeutics

Aquestive Therapeutics, Inc operates as a pharmaceutical company in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder.